Keros Therapeutics (NASDAQ:KROS) Stock Rating Reaffirmed by Piper Sandler

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Sandler in a report issued on Wednesday, Benzinga reports. They currently have a $105.00 price target on the stock. Piper Sandler’s price target would indicate a potential upside of 58.61% from the company’s previous close.

A number of other brokerages have also recently issued reports on KROS. Truist Financial reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 13th. Wells Fargo & Company initiated coverage on Keros Therapeutics in a report on Friday, December 8th. They issued an “overweight” rating and a $60.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Wedbush reaffirmed an “outperform” rating and issued a $86.00 price target on shares of Keros Therapeutics in a report on Thursday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Friday, March 1st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Buy” and a consensus target price of $86.00.

Keros Therapeutics Stock Performance

KROS stock opened at $66.20 on Wednesday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -12.73 and a beta of 1.28. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The stock has a fifty day moving average of $61.61 and a 200-day moving average of $43.91.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Friday, March 1st. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $0.14 million for the quarter. During the same period last year, the firm earned ($1.09) EPS. Equities analysts predict that Keros Therapeutics will post -5.11 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its position in shares of Keros Therapeutics by 29.0% in the 3rd quarter. Barclays PLC now owns 49,511 shares of the company’s stock worth $1,578,000 after buying an additional 11,118 shares during the last quarter. Braidwell LP raised its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock worth $43,271,000 after purchasing an additional 213,444 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Keros Therapeutics by 466.7% in the third quarter. SG Americas Securities LLC now owns 47,183 shares of the company’s stock worth $1,504,000 after purchasing an additional 38,857 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Keros Therapeutics by 12.5% in the second quarter. Principal Financial Group Inc. now owns 6,612 shares of the company’s stock worth $266,000 after acquiring an additional 735 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Keros Therapeutics by 42.1% during the third quarter. Bank of New York Mellon Corp now owns 144,409 shares of the company’s stock valued at $4,604,000 after purchasing an additional 42,771 shares during the period. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.